Figure: Standard curve for IL-33, Soluble (human) Detection Set [For ELISA Application] (Prod. No.
APO-54N-025)."
Please mouse over
Product Details
| Alternative Name: | Interleukin-33, NF-HEV, IL-1F11 |
| |
| Sensitivity: | 5pg/ml (range 0 to 500pg/ml). |
| |
| Assay Time: | 2.5 hours |
| |
| Applications: | ELISA, Colorimetric detection
|
| |
| Application Notes: | For the quantitative determination of soluble human IL-33 from biological fluids (serum and cell culture supernatant). Does not cross-react with mouse IL-33. |
| |
| Wavelength: | 450 nm |
| |
| Species reactivity: | Human
|
| |
| Contents: | 1 vial Standard (lyophilized) (STD)
1 vial Coating Antibody (COAT)
1 vial Detection Antibody (DET) |
| |
| Handling: | For long term storage keep the protein standard at -20°C. Avoid freeze/thaw cycles. |
| |
| Shipping: | Blue Ice |
| |
| Short Term Storage: | +4°C |
| |
| Scientific Background: | Interleukin-1 (IL-1) family members, such as IL-1α/β and IL-18 play important roles in host defense, immune regulation, neuronal injury and inflammation. A member of this family, IL-33, also named Nuclear Factor from High Endothelial Venules (NF-HEV), has been reported to be the specific ligand for ST2, an orphan receptor of the IL-1 receptor family. Structurally, IL-33 is closest to IL-18, rather than IL-1β. The human IL-33 is expressed with a prodomain (aa 1-111) that is cleaved by caspase-1 to produce a 18kDa mature protein (112-270). The stimulation of ST2 by IL-33 induces the NF-κB and MAPK athways. IL-33 is synthesized in response to cytokines such as IL-1β (but also TNFα) and plays an important role in TH2-associated immunology, by triggering an increase secretion of IL-5 and IL-13 from polarized TH2 cells. Overexpression of IL-33 in mice leads to severe pathological changes in mucosal organs. |
| |
| UniProt ID: | O95760 |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue: M. Zeyda, et al.; Int. J. Obes.
37, 358 (2013),
Application(s): IL-33 in human serum,
Abstract;
Human basophils interact with memory T cells to augment Th17 responses: K. Wakahara, et al.; Blood
120, 4761 (2012),
Application(s): IL-33 in mucosal explants,
Abstract;
Full Text
Soluble ST2: a new and promising activity marker in ulcerative colitis: D. Diaz-Jimenez, et al.; World J. Gastroenterol.
17, 2181 (2011),
Application(s): IL-33 in human serum,
Abstract;
Full Text
Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease: C.J. Beltran, et al.; Inflamm. Bowel Dis.
16, 1097 (2010),
Application(s): IL-33 in human serum and biopsy extracts,
Abstract;
Full Text
Interleukin-33 over-expression is associated with liver fibrosis in mice and humans: P. Marvie, et al.; J. Cell. Mol. Med.
14, 1726 (2010),
Application(s): IL-33 in culture supernatants,
Abstract;
Full Text
IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes: I.S. Wood, et al.; Biochem. Biophys. Res. Commun.
384, 105 (2009),
Application(s): IL-33 in culture supernatants and cell lysates,
Abstract;
General Literature References
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines: J. Schmitz, et al.; Immunity
23, 479 (2005),
Abstract;
Interleukin-1 and neuronal injury: S.M. Allan, et al.; Nat. Rev. Immunol.
5, 629 (2005),
Abstract;
ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance: E.K. Brint, et al. ; Nat. Immunol.
5, 373 (2005),
Abstract;
Differences in signaling pathways by IL-1beta and IL-18: J.K. Lee, et al. ; Proc. Natl. Acad. Sci.
101, 8815 (2004),
Abstract;
Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases: F. Martinon & J. Tschopp; Cell
117, 561 (2004),
Abstract;
Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules: E.S. Baekkevold, et al. ; Am. J. Pathol.
163, 69 (2003),
Abstract;
